Industry News

• Aurora Cannabis and EnWave enter licensing, IP partnership and $10 million investment  Aurora Cannabis and EnWave Corporation announced a royalty-bearing commercial license agreement, providing Aurora with the exclusive rights to EnWave’s REV™ drying technology for the production of cannabis materials in the EU. Additionally,
  April 26, 2019  
• Precigen opens gene and cell therapy manufacturing facility in Germantown, Maryland  Precigen, an Intrexon subsidiary, announced the official opening of its new manufacturing facility. Precigen commenced the build-out of the nearly 5,000 square foot manufacturing facility in 2018 to support gene therapy manufacturing.
  April 26, 2019  
• Roche and Spark Therapeutics announce withdrawal and refiling of premerger notification  Roche and Spark Therapeutics announced that Roche has withdrawn its Premerger Notification in connection with Roche's pending acquisition of Spark pursuant to its tender offer to purchase all of the outstanding shares of common stock of Spark for USD 114.50 per Share.
  April 26, 2019  
• Aratana Therapeutics to be acquired by Elanco Animal Health for $245 million  Aratana Therapeutics announced it has signed an agreement to be acquired by Elanco Animal Health, its global collaboration partner on GALLIPRANT® (grapiprant tablets). The deal is structured as a stock-for-stock transaction.
  April 26, 2019  
• Celgene and Acceleron announce submission of luspatercept MAA to the EMA for MDS  Celgene and Acceleron announced that Celgene has submitted a Marketing Authorization Application to the EMA for luspatercept for treatment of adult patients with very low to intermediate-risk myelodysplastic syndromes (MDS)-associated anemia who have ring sideroblasts.
  April 26, 2019  
• Aclaris Therapeutics submits Investigational New Drug Application for ATI-450  Aclaris Therapeutics announced it has submitted an IND Application to the FDA for ATI-450, an oral MK2 inhibitor, for treatment of rheumatoid arthritis. If the IND is allowed by the FDA, Aclaris plans to initiate a Phase 1 clinical trial of ATI-450 in the second half of 2019.
  April 25, 2019  
• ContraVir Pharmaceuticals anounces pricing of $2.14 million public offering  ContraVir Pharma announced the pricing of a public offering with expected total gross proceeds of $2,140,000. Roth Capital Partners is acting as the lead placement agent for the offering. Brookline Capital Markets, a Division of CIM Securities is acting as co-placement agent for the offering.
  April 25, 2019  
• ACADIA Pharma initiates phase 3 CLARITY program with pimavanserin for MDD  ACADIA Pharmaceuticals announced the initiation of the Phase 3 CLARITY-2 study and plans to initiate the Phase 3 CLARITY-3 study in the upcoming months. These studies will evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with major depressive disorder.
  April 25, 2019  
• Hologic launches Trident® HD specimen radiography system in U.S., Canada and Europe  Hologic announced global commercial availability of the Trident® HD specimen radiography system, a next-generation solution that delivers enhanced image quality, improved workflow and instant sample verification during breast-conserving surgeries and stereotactic breast biopsies.
  April 25, 2019  
• Mateon and Oncotelic complete their merger and create a new immuno-oncology company  Mateon Therapeutics and Oncotelic announced they have completed their previously announced merger. The combined company has a focused pipeline of TGF-β RNA Therapeutics for late stage cancers, including gliomas, pancreatic cancer and melanoma.
  April 25, 2019  

   (next 10 articles)